Conclusions
Collectively, surgery may benefit patients with resectable PSC, early
detection and diagnosis are still the best way to obtain the chance of
radical surgery. While chemo-, antiangiogenetic- and immunochemical-
therapy may be useful in controlling the progression of advanced PSC,
relieving symptoms, and extending survival. However, surgical resection
after chemo-, antiangiogenetic- and/or immunochemical- therapy must be
carefully considered in light of the patient’s unique situation.
surgical resection after adjuvant therapy must be carefully considered
in light of the patient’s unique situation. In particular, accurate
tumor cell genetic testing or molecular pathological diagnosis plays a
key role in the individualized treatment of PSC, which could benefit
patients with advanced PSC.